An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.

Publication

An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.

Journal Paper/Review - Jun 5, 2024

Jank Paul, Karn Thomas, van Mackelenbergh Marion T, Lindner Judith L, Treue Denise, Huober Jens, Engels Knut, Solbach Christine, Diebold Kurt, Marme Frederik, Müller Volkmar, Schneeweiss Andreas, Sinn Hans-Peter, Fehm Tanja N, Schem Christian, Stickeler Elmar, Fasching Peter Andreas, Budczies Jan, Felder Bärbel, Nekljudova Valentina, Holtschmidt Johannes, Untch Michael, Denkert Carsten, Loibl Sibylle

Citation

Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, Solbach C, Diebold K, Marme F, Müller V, Schneeweiss A, Sinn H, Fehm T, Schem C, Stickeler E, Fasching P, Budczies J, Felder B, Nekljudova V, Holtschmidt J, Untch M, Denkert C, Loibl S. An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials. Clin Cancer Res 2024

Type

Journal Paper/Review (English)

Journal

Clin Cancer Res 2024

Publication Date

Jun 5, 2024

Issn Electronic

1557-3265

Brief description/objective

The PI3K signaling pathway is frequently dysregulated in breast cancer (BC), and mutations in PIK3CA, are relevant for therapy resistance in HER2pos BC. Mutations in exons 9 or exon 20 may have different impact on response to neoadjuvant chemotherapy-based treatment regimens.